New Coronal Vaccine "Strengthening Needle": Ensure Vaccination Of Key Population And Improve The Level Of Immune Barrier

? ? On September 17, the Zhejiang Provincial Information Office held a press conference, saying that in the near future, it will carry out orderly immunization work for key groups in accordance with the unified national arrangements. On September 16, at a video conference on epidemic prevention and control of key infectious diseases in autumn and winter such as Xinguan pneumonia and influenza in Henan Province, relevant responsible persons also said that Henan would make corresponding preparations to ensure the smooth implementation of immunization work for key groups.

Vaccination and the establishment of population immune barrier are the most economic and effective measures to prevent and control infectious diseases. Many experts have said that it is necessary to strengthen the promotion of vaccination at present. Wang Huaqing, chief expert in immunization program of China CDC, said that more than one billion people have been vaccinated in China. The more people are vaccinated, the more protective the vaccine plays.

From the perspective of necessity, the current global epidemic situation of new coronavirus is developing rapidly, and the new coronavirus is accelerating the mutation and transmission, and the risk of epidemic situation importing into China is high. Internationally, some countries have carried out enhanced immunization. 13 countries, such as the United States, France, Germany, the United Arab Emirates and Israel, have launched or announced the enhanced immunization programs for specific populations. The main targets of vaccination are medical personnel, high-risk groups, the elderly, and people with low immunity. All these provide theoretical basis and practical support for us to strengthen immunization for key groups.

It is also understood that since late July, Pfizer, Modena, Sinopharm group, Kexing biology and other domestic and foreign vaccine manufacturers have successively released the clinical trial results of their own vaccine booster injections. Among these results, the enhanced vaccine can significantly improve the antibody level in the human body, thus enhancing the protective effect of the vaccine.

Medical staff vaccinated citizens at Antai community health service center, Fengqing road sub district office, Jinshui District, Zhengzhou city- Xinhua News Agency

The work of strengthening needle inoculation is about to start

As of September 15, more than 2.16 billion doses of new crown vaccine were reported nationwide, and more than 1 billion people were vaccinated throughout the whole process. Among them, people aged 12-17 have been vaccinated more than 170 million doses, covering 95.287 million people. More than 390 million doses have been given to people over 60 years old, covering more than 200 million people.

It is understood that the state is about to launch the work of strengthening immunization with the new coronavirus vaccine. According to the time requirement of the interval of six months for the 18-59 year-old key population who have completed two doses of inactivated vaccine for six months, in September, October and November of 2021, the number of patients before March 1, April 1, and The key population who have completed two doses of inactivated vaccine before May 1 will be given intensive immunization.

The relevant person in charge of the office of the leading group for the prevention and control of new crown pneumonia in Zhengzhou City, Henan Province, said that the target population calculation, cost guarantee and other preparatory work will be done as soon as possible to ensure the smooth implementation of the immunization work for key groups.

In addition to Henan Province, other regions in China also have arrangements to strengthen vaccination. The person in charge of a county neighborhood committee in Jiangxi told the reporter of the 21st century economic report that according to the government's requirements, all people in the county had been vaccinated before the statistics, which was to do the preliminary investigation for the vaccination booster.

On strengthening vaccination, Shenzhen CDC said that not all people need to be vaccinated. It is not necessary for ordinary people who have completed vaccination within one year.

On August 27, Zheng Zhongwei, head of the vaccine research and development team of the joint prevention and control mechanism research team of the State Council and director of the medical and health science and technology development research center of the National Health Commission, pointed out that there are three categories of people who can carry out intensive vaccination six months after completing the immunization program: the first category is the key personnel facing high input risk, such as customs, border inspection, aviation, isolation points, etc Designated medical institutions and other staff; The second group is the people with relatively low immune function and people over 60 years old; The third category refers to the people who need to go to high-risk areas or countries for work, study and communication.

Wang Huaqing cited people over 60 as an example, "According to the monitoring results of the new crown disease in various countries in the world, the elderly over 60 years old, especially with the increase of age, have a high rate of severe illness and high mortality. In fact, these people need to be hospitalized, treated and rescued after the disease, and the length of stay is relatively long. Therefore, from the strategy of vaccination in various countries, the elderly are especially It is the elderly with basic diseases and one of the top priority groups for vaccination. "

Improve the level of immune barrier

Since late July, Pfizer, Modena, Sinopharm, Kexing biological and other domestic and foreign vaccine manufacturers have successively released the results of phase I and phase II clinical trials of their own booster vaccines. The editorial review of Nature magazine concluded that "in terms of safety, vaccination with the third dose of vaccine will not bring additional safety problems"; And "the third dose of vaccine can at least significantly improve the level of neutralizing antibody".

Prior to that, sinopharma group has submitted the proposal for the third dose of new inactivated coronapneumonia vaccine to relevant departments. Chen Kun, Secretary of China biological discipline inspection commission of sinopharma group, said that relevant experiments have proved that the highest antibody level in subjects can be increased by 5-10 times after the completion of the two injections immunization program six months later, which greatly improves the immune effect. Therefore, it is suggested that for special groups such as the elderly and window service workers, another dose of booster injection can be given within 6 months to 1 year after the completion of the two dose immunization program.

Kexing biology also released the latest research results on the third injection. Compared with the convalescent and 2 doses of new coronal vaccine, the neutralization titers of blood samples from three doses of vaccinated persons to beta, Delta and other variant strains were reduced little. It can be seen that the third dose of vaccine can improve the neutralization breadth of new coronavirus and increase the potential of effective resistance to mutant strains. It was also found that the range of antibody binding activity against the mutant strain induced by three doses of kleyfour was wider than that of the two doses of kleyfour and the convalescent.

In addition, konshino biological also released the protection rate of its reinforcing needle. According to Dr. Zhu Tao, co-founder and chief scientific officer of kangxinuo biological Co., Ltd., the neutralizing antibody level in the body can be increased by about 8 times after the first immunization with the new crown vaccine of adenovirus vector. According to the cross test results of neutralizing antibody, the vaccine has protective effect on the mutant strain.

The reporter of 21st century economic report inquired about the start-up situation of its reinforcing needle from kangxinuo biological Co., Ltd., and the other side said that there was no specific landing arrangement at present; Liu Peicheng, a spokesman for Kexing biology, said that the new crown vaccine was not just an enterprise action, but would be promoted in cooperation with local governments.

?